bet9九州网址

  • <kbd id="sdring" ><rt id="sdring" ><bdo id="sdring" ></bdo></rt></kbd>
  • <source id="sdring" ></source>

    <b id="sdring" ></b>
  • <b id="sdring" ><acronym id="sdring" ><meter id="sdring" ></meter></acronym></b>

        <del id="sdring" ></del>
        Log in
        E-mail
        Password
        Remember
        Forgot password ?
        Become a member for free
        Sign up
        Sign up
        New member
        Sign up for FREE
        New customer
        Discover our services
        Settings
        Settings
        Dynamic quotes 

        MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arcadia Biosciences, Inc.    RKDA

        ARCADIA BIOSCIENCES, INC.

        (RKDA)
          Report  
        SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
        News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

        Arcadia Biosciences : Verdeca Receives Approval of HB4ョ Drought and Herbicide Tolerant Soybeans in Paraguay

        share with twitter share with LinkedIn share with facebook
        share via e-mail
        0
        11/12/2019 | 08:20am EST
        Verdeca Receives Approval of HB4® Drought and Herbicide Tolerant Soybeans in ParaguaySue Wandell2019-11-12T05:07:10-08:00

        - Novel trait stack expected to help growers facing climate and production challenges -
        - HB4 trait now has regulatory approval in top four global suppliers of soybean, accounting for more than 80 percent of the global soybean market -

        DAVIS, Calif. and ROSARIO, Argentina (Nov. 12, 2019) - Verdeca, a joint venture between Arcadia Biosciences, Inc. (Nasdaq: RKDA) and Bioceres Crop Solutions Corp. (NYSE American: BIOX), announced today it has successfully completed the regulatory review process and received approval for its HB4® drought and herbicide tolerant soybeans from the Paraguayan Minister of Agriculture, through the National Commission for Agricultural and Forestry Biosafety.

        The HB4 stack is Verdeca's newest product release from its pipeline of traits developed to benefit soybean producers through quality improvement, stress mitigation and management practices.

        'HB4 is a novel soybean trait that enhances the traditional herbicide tolerance package to provide yield stability across diverse environments,' said Martin Mariani Ventura, general manager of Verdeca. 'Approval of this technology in Paraguay is another significant step for the successful commercialization of HB4 technology in the South American soybean market.'

        With this approval, the HB4 trait now has regulatory approval in more than 80 percent of the global soybean market. The HB4 trait has already been approved in the U.S., Argentina and Brazil, with regulatory submissions currently under consideration by China, among other relevant production and consumption territories. Import approval from China is needed for commercial launch in Argentina and is now expected in late 2020.

        More than 3.5 million of the world's soybean hectares are grown in Paraguay.

        'Trials in Argentina and Brazil have shown a positive impact of the HB4 trait stack on soybean yields,' said Matt Plavan, president and CEO of Arcadia Biosciences. 'We're seeing remarkable excitement in the market from potential seed distribution partners and farmers wanting to grow our drought tolerant and herbicide resistant crop.'

        'This approval in Paraguay is an important step, which not only adds over three million hectares from a market opportunity viewpoint, but also helps us leverage breeding efforts for southern Brazil, where growing conditions are generally similar,' said Federico Trucco, CEO of Bioceres Crop Solutions.

        Arcadia Biosciences and Bioceres Crop Solutions formed Verdeca in 2012 to deploy next-generation soybean traits in all key production regions, beginning in South America and North America.

        About Arcadia Biosciences, Inc.
        Arcadia Biosciences (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia's GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company's portfolio of agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. Arcadia Specialty Genomics™ is a business unit within Arcadia Biosciences dedicated to the optimization and standardization of cannabis plant content, quality, resiliency and yield. For more information, visit www.arcadiabio.com.

        About Bioceres Crop Solutions
        Bioceres Crop Solutions Corp. (NYSE American: BIOX) is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres' solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4® program, the Company is bringing digital solutions to support growers' decisions and provide end-to-end traceability for production outputs. For more information, visit https://investors.biocerescrops.com.

        About Verdeca
        Verdeca, a U.S.-based joint venture between Bioceres Crop Solutions and Arcadia Biosciences, develops and deregulates soybean varieties with next-generation agricultural technologies. Working in partnership with South American growers, Verdeca aims to provide technologies that help increase crop productivity, making more efficient and sustainable use of land and water resources. For more information visit www.verdeca.com.

        Note Regarding Forward-Looking Statements
        This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia's, Bioceres', Verdeca's and their partners' and affiliates' ability to develop commercial products incorporating their traits, and complete the regulatory review process for such products, including obtaining approval from China; Arcadia's and Bioceres' compliance with laws and regulations that impact Verdeca's business, and changes to such laws and regulations; Verdeca's future capital requirements and ability to satisfy its capital needs; and the other risks set forth in Arcadia's and Bioceres' filings with the Securities and Exchange Commission from time to time, including the risks set forth in Arcadia's Annual Report on Form 10-K for the year ended December 31, 2018, Bioceres' Annual Report on Form 20-F for the year ended June 30, 2019, and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. and Bioceres Crop Solutions Corp. disclaim any obligation to update these forward-looking statements.

        Press Contacts:
        Arcadia Biosciences
        Sara Geisner
        +1-314-401-6846
        sara@trailblaze.co

        Bioceres Crop Solutions Corp
        Maximo Goya
        +54-341-4861100
        maximo.goya@biocerescrops.com

        Twitter: @ArcadiaAg
        LinkedIn: Arcadia Biosciences

        Disclaimer

        Arcadia Biosciences Inc. published this content on 12 November 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 November 2019 13:19:01 UTC

        share with twitter share with LinkedIn share with facebook
        share via e-mail
        0
        Latest news on ARCADIA BIOSCIENCES, INC.
        11/12ARCADIA BIOSCIENCES : Verdeca Receives Approval of HB4ョ Drought and Herbicide To..
        PU
        11/06ARCADIA BIOSCIENCES : 3Q Earnings Snapshot
        AQ
        11/06ARCADIA BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
        AQ
        11/06ARCADIA BIOSCIENCES, INC. : Results of Operations and Financial Condition, Finan..
        AQ
        11/06ARCADIA BIOSCIENCES : Announces Third-Quarter 2019 Financial Results and Busines..
        PU
        11/05ARCADIA BIOSCIENCES : Announces Wheat Purchase Commitment, Significant Increase ..
        PU
        10/30ARCADIA BIOSCIENCES : What the USDA's Interim Final Rule Means for U.S. Hemp Cul..
        PU
        10/21ADVENTURES IN HEMP BREEDING : improving uniformity
        PU
        10/15ARCADIA BIOSCIENCES : Advances Hemp Operations with Archipelago™ Ventures
        PU
        10/07ARCADIA BIOSCIENCES : Change in Directors or Principal Officers, Financial State..
        AQ
        More news
        Financials (USD)
        Sales 2019 1,50 M
        EBIT 2019 -20,1 M
        Net income 2019 -27,3 M
        Debt 2019 -
        Yield 2019 -
        P/E ratio 2019 -0,96x
        P/E ratio 2020 -1,95x
        Capi. / Sales2019 23,5x
        Capi. / Sales2020 4,06x
        Capitalization 35,4 M
        Chart ARCADIA BIOSCIENCES, INC.
        Duration : Period :
        Arcadia Biosciences, Inc. Technical Analysis Chart | MarketScreener
        Full-screen chart
        Technical analysis trends ARCADIA BIOSCIENCES, INC.
        Short TermMid-TermLong Term
        TrendsBearishNeutralNeutral
        Income Statement Evolution
        Consensus
        Sell
        Buy
        Mean consensus HOLD
        Number of Analysts 3
        Average target price 15,00  $
        Last Close Price 4,09  $
        Spread / Highest target 291%
        Spread / Average Target 267%
        Spread / Lowest Target 242%
        EPS Revisions
        Managers
        NameTitle
        Matthew T. Plavan President, Chief Executive Officer & Director
        Kevin J. Comcowich Chairman
        Pamela Haley Chief Financial Officer
        Randy Shultz Head-Research & Development
        Gregory D. Waller Independent Director
        Sector and Competitors
        1st jan.Capitalization (M$)
        ARCADIA BIOSCIENCES, INC.29.02%35
        SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.-37.10%6 230
        ISRAEL CHEMICALS LTD.-23.54%5 953
        THE SCOTTS MIRACLE-GRO COMPANY73.40%5 914
        UPL LTD6.71%5 685
        PHOSAGRO PAO--.--%4 950
        bet9九州网址

            ,